Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Pancreatic cancer is a highly lethal malignancy with limited effective systemic therapies.
• Urgent need exists for predictive biomarkers to guide treatment decisions in pancreatic cancer.
• Existing treatments often show heterogeneous responses, necessitating personalized therapeutic strategies.

Purpose of the Study:

• To develop and utilize a patient-derived organoid (PDO) library to model pancreatic cancer.
• To assess PDOs' ability to predict patient response to various chemotherapeutic and investigational agents.
• To identify novel therapeutic strategies and biomarkers for pancreatic cancer through organoid profiling.

Main Methods:

• Generation of a library of pancreatic cancer patient-derived organoids (PDOs).
• Comprehensive genomic and transcriptomic profiling of PDOs to mirror primary tumors.
• Therapeutic profiling of PDOs using standard-of-care and investigational agents.
• Derivation of organoid-based gene expression signatures for chemosensitivity prediction.

Main Results:

• PDOs successfully recapitulated the mutational spectrum and transcriptional subtypes of primary pancreatic cancer.
• PDOs demonstrated heterogeneous responses to diverse therapeutic agents, mirroring patient outcomes.
• Organoid-based gene expression signatures accurately predicted patient responses to chemotherapy in both adjuvant and advanced settings.
• Therapeutic profiling of PDOs identified potential alternative treatments for chemorefractory cases.

Conclusions:

• Combined molecular and therapeutic profiling of PDOs can predict clinical response in pancreatic cancer.
• PDOs serve as a valuable platform for precision medicine, enabling prospective therapeutic selection.
• This approach holds promise for improving survival and quality of life for pancreatic cancer patients.